Europe Radiopharmaceuticals Market

Europe Radiopharmaceuticals Market Size 

The Europe Radiopharmaceuticals Market was valued at USD 2.09 billion in 2024. The Europe Radiopharmaceuticals Market is expected to have 11.4% CAGR from 2025 to 2033 and be worth USD 5.52 billion by 2033 from USD 2.33 billion in 2025.  

The growing patient population suffering from chronic diseases is majorly driving the European Radiopharmaceuticals market growth. Radiopharmaceuticals play a significant role in treating thyroid tumors and other types of cancer, such as neuroendocrine tumors, prostate cancer, metastatic bone cancer, and neuroblastoma, and for the palliative treatment of liver cancer. Radiopharmaceuticals is used for early disease detection through diagnosis leading to early treatment and preventing critical conditions. Radiopharmaceuticals uses a radioactive substance to examine diseases. Nearly 10 million European patients benefit from Radiopharmaceuticals in diagnosing and treating cancer and cardiovascular disease yearly.

The rising prevalence of neurological and orthopedic diseases is boosting the growth rate of the European Radiopharmaceuticals market. The increasing number of psychiatric suicide cases also lead to a demand for Radiopharmaceuticals. Radiopharmaceuticals helps to detect the brain's functionality by using Pico molar amounts of radiopharmaceuticals to detect image changes in the brain. With growing age, many people suffer from orthopedic issues and prefer to have Radiopharmaceuticals diagnostic procedures for accurate results. Sports persons also use Radiopharmaceuticals to diagnose sports injuries and other issues such as avascular necrosis, bone tumors, metabolic bone diseases and others.

The growing number of advancements in the development of devices and equipment is another notable factor contributing to the growth of the Radiopharmaceuticals market in Europe. Radiopharmaceuticals has a high growth rate due to the increasing use of Radiopharmaceuticals in several applications, such as radioactive iodine therapy and brachytherapy. It is also used for full-body imaging and helps in developing personalized medicine. Advanced technologies such as artificial intelligence are also used in Radiopharmaceuticals, which allows Radiopharmaceuticals physicians to focus on more complex activities. Additionally, increasing government investment and developing radiopharmaceutical medicine propel the European Radiopharmaceuticals market growth.

In addition, the growing demand to improve diagnostic and treatment procedures, the emergence of new applications in radiopharmaceuticals with advanced technology significantly and growing expenditure on healthcare are favoring the Radiopharmaceuticals market in Europe. The rise in the need for targeted treatment procedures, growing disposable income in urban areas, and rising support from the government and non-government organizations through funds for developing Radiopharmaceuticals are also supporting the market in the European region. The rise in awareness over the availability of various treatment procedures among people and ongoing research on developing new treatment procedures for different diseases at low cost are fuelling the growth rate of the European Radiopharmaceuticals market.

On the other hand, the high costs associated with the devices used for diagnosing patients using Radiopharmaceuticals are majorly hampering the growth of the European Radiopharmaceuticals market. Other factors such as low hospital budgets, less image quality in refurbished devices, and a need for more awareness of the procedures further hinder the growth of the European Radiopharmaceuticals market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The PET segment is predicted to hold the major share of the European Radiopharmaceuticals market during the forecast period.

By Application Insights

The oncology segment is expected to hold the largest share of the European Radiopharmaceuticals market during the forecast period owing to the growing prevalence of cancer in the European region and the rising usage of Radiopharmaceuticals in cancer treatment procedures.

COUNTRY LEVEL ANALYSIS

Regionally, Europe is one of the fastest-growing regions worldwide and accounted for a substantial share of the global market in 2024. The growth of the European market is majorly driven by the growing advancements in the healthcare sector in Europe. Several post-graduation courses are available in Europe regarding Radiopharmaceuticals. In addition, the governments of Europe have conducted programs among the patient about the benefits of Radiopharmaceuticals diagnosis and how it helps patients with accurate treatment and fast cures.

Germany held a significant share in the Europe region in 2023 owing to the rise in capital income. Besides, the adoption of the latest technological developments in clinical centers is leveraging the growth rate of the market. Following Germany, U.K. and France had a considerable share of the European region in 2024. The rise in awareness over SPECT and PET diagnostic procedures for accurate results is fuelling the Radiopharmaceuticals market's growth. Increasing concern towards health and people's demand for effective diagnostic and treatment procedures is prompting the demand for this market. Italy, Spain, Russia, and the Rest of Europe are anticipated to have a significant growth rate in foreseen years with the hospitals and diagnostic centers’ growing investments.

The UK Radiopharmaceuticals market is estimated to hold a considerable share of the European market during the forecast period. The UK market growth is driven by the increasing awareness about Radiopharmaceuticals among the population. The government has conducted several training procedures for healthcare providers to know about Radiopharmaceuticals and how it works to increase the success rate of the diagnosis. Increasing research and development for Radiopharmaceuticals and the increasing number of Radiopharmaceuticals institutes in the UK are further propelling the Radiopharmaceuticals market growth in the UK.

KEY MARKET PLAYERS

Companies playing a notable role in the European Radiopharmaceuticals market and profiled in this report are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.

MARKET SEGMENTATION

This research report on the European Radiopharmaceuticals market has been segmented and sub-segmented into the following categories

By Type

• Diagnostic Radioisotopes

  • SPECT   

    • Technetium-99m

    • Thallium-201

    • Gallium-67

    • Iodine-23

    • Others

  • PET     

    • Fluorine-18

    • Rubidium-82

    • Others

• Therapeutic Radioisotopes                

  • Beta Emitters   

    • Iodine-131

    • Yttrium-90

    • Samarium-153

    • Rhenium-186

    • Lutetium-177

  • Alpha Emitters  

    • Radium-223

  • Brachytherapy  

    • Cesium-131

    • Iodine-125

    • Palladium-103

    • Iridium-192

By Application

• Cardiology

• Lymphoma

• Thyroid           

• Neurology        

• Oncology         

• Others

By Country

• UK

• France

• Spain

• Germany

• Italy

• Russia

• Sweden

• Denmark

• Switzerland

• Netherlands

• Turkey

• Czech Republic

• Rest of Europe